Short-Term Debt to Equity Ratio: Cerevel Therapeutics (CERE)
This chart of the market price for Cerevel Therapeutics (CERE) reflects the performance of the company developing drugs for CNS disorders, where the indicator stands at 0.00. The business's success relies on the results of final emraclidine trials for the treatment of Alzheimer's and schizophrenia. A team of top neurobiologists is being attracted by generous capital to combat Parkinson's disease. Upon FDA approval, inelastic demand will enable the company to establish high pricing power for its medications.
Metric breakdowns and analytics for cerevel.com (CERE)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Cerevel Therapeutics|CERE - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Cerevel Therapeutics, Inc.|CERE - Company Cumulative Debt|Debt to Book Capitalization Ratio Cerevel Therapeutics Inc|CERE - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cerevel Therapeutics|Quick Liquidity Indicator cerevel.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:CERE Cerevel
To verify the issuer's financial stability, investors analyze the share of short-term liabilities within the capital structure, where the historical ratio of short-term loans to equity reflects liquidity risk in financing the development of neurobiological drugs for the treatment of Parkinson's disease: an increasing ratio signals a dependence on external borrowing, while a decrease confirms the ability of Cerevel Therapeutics (CERE) to autonomously support high-tech research.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|BHVN - Current Liabilities to Capital|Short-Term Debt to Equity Amylyx AMLX|Ratio of Short-Term Indebtedness to Capital TRVI|Praxis Precision Medicines - Short-Term Debt to Capital|Current Liabilities to Capital anavex.com|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|PRTA (Prothena Biosciences) - Short-Term Debt to Equity|ALEC (Alector Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Equity Omeros Corporation (OMER)|Short-Term Debt to Equity NGNE (neurogene.com)|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA: Short-Term Debt to Equity Ratio|Scilex Holding Company, Inc. - Short-Term Loans to Capital Ratio|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. - Ratio of Short-Term Indebtedness to Capital|CGTX (Cognition Therapeutics, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Inhibikase Therapeutics Inc IKT|Short-Term Debt to Equity Cassava (SAVA)|ASRT (assertiotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital COYA (Coya Therapeutics)|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|OVID - Short-Term Debt to Equity|Current Liabilities to Equity ABOS|CRVO: Short-Term Debt to Capital|Current Liabilities to Capital Alterity Therapeutics Limited (ATHE)|Short-Term Debt to Equity Ratio CLNN|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Ratio JUNS (Jupiter Neurosciences)|Short-Term Loans to Capital Ratio RLMD|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Short-Term Debt to Capital Coefficient Grace Therapeutics Inc (GRCE)|Firefly Neuroscience, Inc - Short-Term Debt to Capital|Klotho Neurosciences Inc (KLTO) - Short-Term Debt to Equity Ratio|neurosense-tx.com (NRSN) - Short-Term Debt to Equity|RVPH - Short-Term Debt to Capital Coefficient|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio NeurAxis Inc (NRXS)|Short-Term Debt to Capital HSDT|PASG - Current Liabilities to Capital|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|Ratio of Short-Term Indebtedness to Capital NERV|Athira - Short-Term Debt to Capital|Current Liabilities to Capital Addex|alzamend.com (ALZN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio CYCN|PTIX (Protagenic Therapeutics Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Pasithea KTTA|Short-Term Debt to Equity Ratio CRGT (Cortigent, Inc.)|Short-Term Debt to Capital Avenue Therapeutics Inc (ATXI)|Short-Term Debt to Equity Brainstorm Cell BCLI|Ratio of Short-Term Indebtedness to Capital CARA|CHRO - Short-Term Debt to Equity|Current Liabilities to Capital Eliem Therapeutics|ITCI: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Longboard|MRNS (Marinus Pharmaceuticals) - Short-Term Debt to Capital|Current Liabilities to Capital nkgenbiotech.com NKGN|Short-Term Debt to Equity NeuroBo Pharmaceuticals, Inc. (NRBO)|SAGE (Sage Therapeutics Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SNPX (Neurotrope)|Trevena Inc (TRVN) - Current Liabilities to Capital|VIGL: Short-Term Debt to Equity Ratio|WENA: Short-Term Debt to Equity